Publication: 2164

Publication: 2164

5-year Follow-up of a Randomized Controlled Trial of Immediate versus Delayed Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women with Breast Cancer Starting Letrozole after Tamoxifen: N03CC (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Cancer vol 121 (15) 2537-2543

Year:: 2015
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Long-Term-Followup
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 4

Parents:: None
Children:: None

Program:: CCP
Primary Committee:: Symptom Inter
Sec. Committees:

Pharmas:
Grants:: N01 CA035431, U10 CA035269, CA-37404, U10 CA031946, U10 CA033601, U10 CA037404, U10 CA180821, CA-35103, CA-25224, UG1 CA189823, P30 CA015083, U10 CA035415, CA-35415, U10 CA035431, UG1 CA189808, CA-35269, U10 CA025224, U10 CA035103

Corr. Author:: Nina D. Wagner-Johnston
Authors:: Nina D. Wagner-Johnston Jeff A. Sloan Heshan Liu Ann E. Kearns Stephanie L. Hines Suneetha Puttabasavaiah Shaker R. Dakhil Jacqueline M. Lafky Edith A. Perez Charles L. Loprinzi

Networks:: KS055, LAPS-MD017, LAPS-MN026, PR028

Study: NCCTG-N03CC
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: zoledronic acid, bone loss, postmenopausal, breast cancer, letrozole, tamoxifen